Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.

Trial Details

NCT ID
NCT06041776
Phase
PHASE3
Sponsor
Betta Pharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Befotertinib + Icotinib placebo
  • Icotinib + Befotertinib placebo
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Nanjing, China|32.06167,118.77778
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Willingness to sign informed consent prior to any study specific procedures, and ability to with scheduled visits, treatment plans, laboratory test…
  • Male or female, aged at least 18 years.
  • Histologically confirmed primary NSCLC, and mainly non-squamous cell carcinoma (including mixed type carcinoma mainly composed of adenocarcinoma co…
  • Absence of brain metastasis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →